Literature DB >> 15843498

Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.

Zhi-Yuan Xu1, Martin Loignon, Fei-Yu Han, Lawrence Panasci, Raquel Aloyz.   

Abstract

Eukaryotic cells respond to DNA damage by activation of DNA repair, cell cycle arrest, and apoptosis. Several reports suggest that such responses may be coordinated by communication between damage repair proteins and proteins signaling other cellular responses. The Rad51-guided homologous recombination repair system plays an important role in the recognition and repair of DNA interstrand crosslinks (ICLs), and cells deficient in this repair pathway become hypersensitive to ICL-inducing agents such as cisplatin and melphalan. We investigated the possible role of the Rad51-paralog protein Xrcc3 in drug resistance. Xrcc3 overexpression in MCF-7 cells resulted in 1) a 2- to 6-fold resistance to cisplatin/melphalan, 2) a 2-fold increase in drug-induced Rad51 foci, 3) an increased cisplatin-induced S-phase arrest, 4) decreased cisplatin-induced apoptosis, and 5) increased cisplatin-induced DNA synthesis arrest. Interestingly, Xrcc3 overexpression did not alter the doubling time or cell cycle progression in the absence of DNA damage. Furthermore, Xrcc3 overexpression is associated with increased Rad51C protein levels consistent with the known interaction of these two proteins. Our results demonstrate that Xrcc3 is an important factor in DNA cross-linking drug resistance in human tumor cells and suggest that the response of the homologous recombinational repair machinery and cell cycle checkpoints to DNA cross-linking agents is intertwined.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843498     DOI: 10.1124/jpet.105.084053

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  28 in total

1.  Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer.

Authors:  Chunyan Liu; Shaoyu Zhou; Shahnaz Begum; David Sidransky; William H Westra; Malcolm Brock; Joseph A Califano
Journal:  Lung Cancer       Date:  2006-11-21       Impact factor: 5.705

Review 2.  The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance.

Authors:  Deepa Sampath; William Plunkett
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

3.  Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin.

Authors:  Kriste A Lewis; Kia K Lilly; Evelyn A Reynolds; William P Sullivan; Scott H Kaufmann; William A Cliby
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

Review 4.  Targeting the homologous recombination pathway by small molecule modulators.

Authors:  Fei Huang; Alexander V Mazin
Journal:  Bioorg Med Chem Lett       Date:  2014-05-06       Impact factor: 2.823

5.  A role for homologous recombination proteins in cell cycle regulation.

Authors:  Kaja Kostyrko; Sandra Bosshard; Zuzanna Urban; Nicolas Mermod
Journal:  Cell Cycle       Date:  2015-06-30       Impact factor: 4.534

6.  Chemoresistant lung cancer stem cells display high DNA repair capability to remove cisplatin-induced DNA damage.

Authors:  Wai-Kin Yu; Zhigang Wang; Chi-Chun Fong; Dandan Liu; Tak-Chun Yip; Siu-Kie Au; Guangyu Zhu; Mengsu Yang
Journal:  Br J Pharmacol       Date:  2017-01-16       Impact factor: 8.739

7.  FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.

Authors:  Nu Zhang; Xinjian Wu; Lixuan Yang; Feizhe Xiao; Heng Zhang; Aidong Zhou; Zhengsong Huang; Suyun Huang
Journal:  Clin Cancer Res       Date:  2012-09-12       Impact factor: 12.531

8.  A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.

Authors:  David Abasiwani Alagpulinsa; Shmuel Yaccoby; Srinivas Ayyadevara; Robert Joseph Shmookler Reis
Journal:  Cancer Biol Ther       Date:  2015-05-21       Impact factor: 4.742

9.  Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Authors:  Robert L Dilley; Weijie Poh; Douglas E Gladstone; James G Herman; Margaret M Showel; Judith E Karp; Michael A McDevitt; Keith W Pratz
Journal:  Leuk Res       Date:  2013-12-30       Impact factor: 3.156

10.  Protective role of Puralpha to cisplatin.

Authors:  Rafal Kaminski; Armine Darbinyan; Nana Merabova; Satish L Deshmane; Martyn K White; Kamel Khalili
Journal:  Cancer Biol Ther       Date:  2008-12-08       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.